Mdm2 oncoprotein plays a major role in inhibiting the p53 tumor suppressor protein. Here, we investigate phosphorylation of Mdm2 at serine 407 (S407). S407 is phosphorylated in cells after treatment with camptothecin (CPT) or hydroxyurea, inhibitors of DNA replication. S407 phosphorylation after CPT treatment is induced upon cell cycle arrest during S phase and prevented if entry into S phase of cell cycle is blocked. We found that a major kinase responsible for S407 phosphorylation is ATR, a DNA damage checkpoint protein that induces cell cycle arrest and promotes DNA repair in response to impaired DNA replication; induction of S407 phosphorylation is enhanced after expression of wild-type ATR, while it is inhibited by a dominant-negative form of ATR. Further, S407 is specifically phosphorylated by ATR in vitro. Substitution of S407 with aspartate (S407D), but not with alanine (S407A), promotes nuclear localization of p53. Taken together, our data indicate that S407 phosphorylation of Mdm2 by ATR reduces Mdm2-dependent export of p53 from nuclei to cytoplasm.
Introduction
The p53 tumor suppressor protein plays a major role in preventing tumorigenesis. In a large number of tumor cells, deletions or inactivating mutations of the p53 gene are found (Olivier et al., 2002) . p53 functions as a sensor to detect harmful alterations of the genome that might eventually cause malignant transformation of damaged cells (Lane, 1992) . Activated p53 turns on its downstream genes, which serve to block the emergence of cancer cells by inducing a variety of biological outcomes such as cell cycle arrest or apoptosis (Levine, 1997) .
When cells are not exposed to any stimuli that can activate p53, activity of p53 are maintained at a low level mainly as a result of its inhibition by Mdm2 oncoprotein (Lane and Hall, 1997; Prives, 1998; Juven-Gershon and Oren, 1999) . Mdm2 inactivates p53 by (i) promoting p53 degradation by functioning as an E3 ubiquitin ligase for p53, (ii) exporting p53 from nuclei to cytoplasm where degradation of the majority of p53 takes place, and (iii) blocking the N-terminal trans-activating domain of p53 (Momand et al., 2000) . Mdm2 itself is a direct transcriptional target of p53, thus forming a negative feedback loop with p53 (Barak et al., 1993; Wu et al., 1993) . p53 is induced by various endogenous or exogenous stimuli. Activation of an oncogene, such as ras or E1A, induces expression of another important tumor suppressor protein, p14/ARF. Induction of p14/ARF suppresses Mdm2 function, and thereby leads to p53 activation (Sherr, 1998) .
p53 activation is also caused by various genotoxic insults such as DNA damage. It has been demonstrated that phosphorylation of p53 plays an important role in activating p53 after DNA damage. For example, DNA damage induces phosphorylation of p53 at serine 15 and serine 20. Phosphorylation at serine 15 causes nuclear retention of p53 and facilitation of binding of p300 to p53, while phosphorylation at serine 20 inhibits binding of Mdm2 to p53 (Prives, 1998; Chehab et al., 1999; Zhang and Xiong, 2001 ). Thus, phosphorylation of these sites contributes to p53 activation. Another example of p53 phosphorylation induced after DNA damage is phosphorylation at serine 46. Phosphorylation of serine 46 is induced only after cells are exposed to heavy DNA damage, and is associated with induction of apoptotic cell death and induction of p53AIP1, a p53 downstream target gene that is involved in p53-dependent induction of apoptosis (Oda et al., 2000) .
Although phosphorylation of p53 is important for regulation of p53 function (Giaccia and Kastan, 1998) , it does not fully explain how p53 is activated after DNA damage (Ashcroft et al., 2000) . Recent reports demonstrate that Mdm2 phosphorylation is also important for p53 activation after exposure of cells to genotoxic stress. Serine 395 and tyrosine 394 of human Mdm2 are phosphorylated after DNA damage, and analyses of the corresponding mutants indicate that phosphorylation of Mdm2 at these sites activates p53 via downregulation of Mdm2 function (Maya et al., 2001; Goldberg et al., 2002) .
Eucaryotic cells have well-conserved mechanisms to defend them against genotoxic stress. Members of the phosphatidyl inositol-3 kinase (PI-3K)-related protein kinase family play a major role in protecting cells from DNA damage. Most known members of the PI-3K family are conserved from yeast to human, and mainly serve to preserve the stability of the genome against various genotoxic insults. In mammalian cells, ATM and ATR have emerged as two major kinases in the PI-3K family (Kastan and Lim, 2000; Abraham, 2001) . ATM is activated after double-strand breaks, while ATR activation is induced in response to halted DNA replication (Abraham, 2001 ). Activated ATM and ATR then protect cells from detrimental DNA damage by inducing cell cycle arrest and promoting DNA repair.
Elucidation of kinases that are responsible for phosphorylation of p53 and Mdm2 after DNA damage revealed that both ATM and ATR are involved in p53 activation. ATM phosphorylates p53 at serine 15 (Banin et al., 1998; Canman et al., 1998) , and Mdm2 at serine 395 (Maya et al., 2001) . ATM is also responsible for phosphorylation of p53 at serine 20 via phosphorylation and activation of Chk2 kinase (Chehab et al., 2000; Hirao et al., 2000; Shieh et al., 2000) . In fact, phosphorylation of these sites by ATM leads to activation of p53 (Siliciano et al., 1997; Chehab et al., 1999; Hirao et al., 2000; Shieh et al., 2000) .
Meanwhile, ATR phosphorylates p53 at serine 15 after DNA damage in response to UV or hypoxiainduced replication arrest Hammond et al., 2002) . Notably, the kinetics of serine 15 phosphorylation induced by ATR is slow in comparison to that induced by ATM. Thus, phosphorylation of p53 by ATR contributes to a prolonged induction of p53 after DNA damage.
In this paper, we report that Mdm2 is a novel member of substrates for ATR kinase. We demonstrate that ATR is responsible for phosphorylation of Mdm2 at serine 407 both in vivo and in vitro. Further, analyses of Mdm2 mutants indicate that serine 407 phosphorylation attenuates Mdm2-dependent export of p53 from nuclei to cytoplasm, thus leading to nuclear retention of p53. Implication of Mdm2 phosphorylation by ATR will be discussed.
Results

Serine 407 of Mdm2 is phosphorylated in vivo
Inspection of the primary sequence of Mdm2 revealed that there exists a cluster of S/T-Q motifs at the flanking region of the RING finger domain (Figure 1a ). S/T-Q motifs were previously identified as consensus sequences that are phosphorylated by kinases that belong to the PI-3K family (Kim et al., 1999) . In the flanking region of the RING finger domain, serine 388, 395, and 407 correspond to the consensus S/T-Q motif, and are well conserved among different species (Figure 1a) . In fact, it was previously demonstrated that serine 395 was phosphorylated by ATM, a member of the PI-3K family (Maya et al., 2001 ).
Serine 407 (S407) is probably the most conserved S/T-Q site in the S/T-Q cluster. Therefore, it is of interest to examine if this site is phosphorylated in cells, and if phosphorylation of S407 affects functions of Mdm2. In order to determine whether S407 is phosphorylated in vivo, we raised the anti-Mdm2 antibody that recognizes phosphorylated S407. First, we examined if the antibody specifically recognizes phosphorylated S407 (Figures  1b-d) . To determine whether the antibody recognizes phosphorylated Mdm2, we immunoprecipitated endogenous Mdm2 with the anti-Mdm2 antibody (IF-2) CV-1 cells were transfected with wildtype or the mutant Mdm2 (S407A) as described above, and transfected cells were fixed with 4% paraformaldehyde followed by permeabilization with methanol, and used for double-immunostaining with the anti-Flag antibody (M2) and the anti-phospho-S407 antibody. Identical settings for the microscope were used to take photographs for cells that express wild-type and the mutant Mdm2. In the right panel, immunostaining of CV-1 cell transfected with wild-type Mdm2 is shown with a higher magnification Role of Mdm2 phosphorylation by ATR in p53 nuclear export T Shinozaki et al from COS-1 cells that were treated with camptothecin (CPT), an inhibitor of DNA topoisomerase. Immunoprecipitates were incubated with buffer alone, calf intestine alkaline phosphatase (CIAP), or CIAP plus a phosphatase inhibitor (sodium orthovanadate). Immunoprecipitates were then used for Western blot analysis with the anti-phospho-S407 antibody. The reactivity of the antibody for Mdm2 was lost if the immunoprecipitated Mdm2 was incubated with CIAP ( Figure 1b , lane 2). The negative effect of the phosphatase on the reactivity of the anti-phospho-S407 antibody for Mdm2 was neutralized in the presence of the phosphatase inhibitor (Figure 1b, lane 3) . These results indicate that the raised antibody recognizes phosphorylated Mdm2.
Next, we determined if the integrity of S407 is required for the recognition of Mdm2 by the antiphospho-S407 antibody. Wild-type Mdm2 or its mutant with substitution of S407 with alanine (S407A) was transfected into CV-1 cells, and detected with the antibody by Western blot analysis (Figure 1c ) or immunostaining ( Figure 1d ). In both assays, the antiphospho-S407 antibody reacted with wild-type Mdm2, but not with the S407A mutant (Figure 1c and 1d) . In contrast, the Mdm2 mutant with an alanine substitution at serine 166 (S166A) was detected by the antibody with an affinity comparable to wild-type Mdm2 (data not shown). Combined with data in Figure 1b , these results indicate that the raised antibody specifically reacts with phosphorylated S407 of Mdm2.
Phosphorylation at S407 is markedly induced in cells after CPT treatment
As an initial step to understand the role of phosphorylation of S407 on p53 activation after DNA damage, we examined if phosphorylation of S407 is induced in CV-1 cells after various treatments that are known to activate p53. Protein levels of Mdm2 were represented by Western analysis with the monoclonal antibody IF-2, whose reactivity is not affected by the phosphorylation status of the protein. Phosphorylation of S407 was markedly induced 24 h after CPT treatment (Figure 2a) . At long exposure, S407 phosphorylation was also detected if cells were treated with diferroxamine, UV, or gamma irradiation. In contrast, we detected no phosphorylation at S407 after treatment with a proteosome inhibitor (LLnL) or actinomycin D. In order to determine whether strong induction of S407 phosphorylation by CPT did not merely reflect increased levels of Mdm2, we treated cells with another proteosome inhibitor, MG132, in the absence or the presence of CPT, and examined induction of S407 phosphorylation by CPT (Figure 2b ). After incubation of cells with MG132, comparable levels of Mdm2 are expressed either in the presence or the absence of CPT. Under these conditions, we observed S407 phosphorylation only in the presence of CPT. Thus, CPT treatment induces S407 phosphorylation in CV-1 cells.
Induction of S407 phosphorylation by CPT prompted us to perform a time course analysis of induction of the phosphorylation after the drug treatment to determine the kinetics of induction of the phosphorylation (Figure 2c ). Mdm2 expression was detected by IF-2 in 6 h, and levels of Mdm2 increased gradually up to 24 h after CPT treatment. In contrast, S407 phosphorylation was not detected until 9 h after CPT treatment, and levels of the phosphorylation then increased until 24 h after the treatment, thus indicating that S407 phosphorylation was induced with a slow kinetics after CPT treatment.
Phosphorylation at S407 is associated with cell cycle arrest at S phase
The slow kinetics of induction of S407 phosphorylation after CPT treatment suggested the possibility that its phosphorylation is induced as a consequence of an accumulation of cells at a certain point of cell cycle. Since CPT blocks DNA synthesis by inhibiting DNA topoisomerase I (Wang et al., 2002) , we speculated that S phase arrest induced after CPT treatment may be prerequisite for S407 phosphorylation.
In order to determine whether entry of cells into S phase after CPT treatment is associated with S407 phosphorylation, we examined the phosphorylation in synchronized cells. CV-1 cells were incubated in a medium containing low serum to induce cell cycle arrest at G0/G1 phase, and after re-entry into cell cycle by serum stimulation, a kinetics of S407 phosphorylation was examined either in the presence or the absence of CPT (Figure 3a) . Entry of cells into S phase was simultaneously monitored by BrdU incorporation into cells.
In the absence of CPT, BrdU incorporation increased until 12 h after serum induction, and gradually declines after 12 h as the cells exit S phase. Significant increase of Role of Mdm2 phosphorylation by ATR in p53 nuclear export T Shinozaki et al S407 phosphorylation was not detected during the time course, indicating that entry into S phase per se is not sufficient for S407 phosphorylation. In contrast, a percentage of BrdU-positive cells did not decline after 12 h in the presence of CPT, indicating that progression of cell cycle from S phase into G2 phase was delayed due to CPT treatment. Under these conditions, in which cells were stalled in S phase, a drastic increase of S407 phosphorylation was detected. These results strongly suggest that S407 phosphorylation is induced in response to halted S phase progression after CPT treatment.
Next, we treated cells with CPT in the presence or the absence of mimosine, an inhibitor of cell cycle at late G1 phase, and determined the levels of S407 phosphorylation. As expected, treatment of cells with CPT alone induced cell cycle arrest at S phase (Figure 3b , left panel). Treatment of cells with CPT together with mimosine caused cell cycle arrest at G1 phase, thus preventing CPT-mediated S phase arrest by blocking entry of cells into S phase (Figure 3b, left panel) . Under these conditions, treatment of cells with mimosine effectively abrogated S407 phosphorylation by CPT (Figure 3b , right panel, lanes 3 and 4), further suggesting that entry into S phase is necessary for S407 phosphorylation after treatment of cells with CPT.
Finally, we treated CV-1 cells with hydroxyurea (HU), an inhibitor of DNA elongation, and examined the role of blockage of DNA replication on S407 phosphorylation. In fact, HU treatment induced phosphorylation at S407 as well as S166 (Figure 3c ). Taken together, these data indicate that an inhibition of DNA replication leads to S407 phosphorylation.
It was previously demonstrated that S166 is phosphorylated by Akt kinase (Mayo and Donner, 2001; Zhou et al., 2001; Ashcroft et al., 2002; Gottlieb et al., 2002; Ogawara et al., 2002) . Caffeine blocks S166 phosphorylation (Figure 3b ). It was shown that Akt kinase is activated by PI-3K (Burgering and Coffer, 1995; Franke et al., 1995) , and the kinase activity of PI-3K is inhibited by caffeine at high concentrations in vitro (Hall-Jackson et al., 1999) . It may be possible, therefore, that caffeine reduces phosphorylation of S166 by inhibiting PI-3K.
ATR is responsible for S407 phosphorylation after DNA damage in vivo We suspected that the kinase that phosphorylates S407 is ATR among members that belong to the PI-3K family for the following reasons. First, S407 phosphorylation phosphorylation by CPT in the presence of MG132. CV-1 cells were incubated with or without 1 mM CPT for 24 h. Cells were incubated with 50 mM MG132 for 5 h before harvesting, and lysates prepared from these cells were used to immunoprecipitate Mdm2 with IF-2. The immunoprecipitates were then analysed by Western blot analysis with IF-2 or the anti-phospho-S407 antibodies. (c) S407 phosphorylation was induced after CPT treatment with a slow kinetics. CV-1 cells were incubated with 1 mM CPT for the indicated period, and lysates prepared from these cells were used for Western blot analysis with the anti-p53 antibody (DO-1) or the anti actin antibody. Alternatively, the lysates were used to immunoprecipitate Mdm2 with IF-2, and the immunoprecipitates were analysed by Western blot analysis with the anti-Mdm2 monoclonal antibody (IF-2) or with the anti-phospho-Mdm2 antibodies (the anti-phospho-S166 and -S407 antibodies)
Role of Mdm2 phosphorylation by ATR in p53 nuclear export T Shinozaki et al was induced after HU and CPT treatment, and both treatments are known to block DNA replication and activate ATR (Wang et al., 2002) . Second, S407 phosphorylation was blocked by caffeine ( Figure 3b , lane 5), which can block kinase activities of ATR as well as ATM (Hall-Jackson et al., 1999; Sarkaria et al., 1999) . Third, the slow kinetics of induction of S407 phosphorylation after CPT treatment makes ATR a better candidate than ATM, since ATR, but not ATM, is activated with a slow kinetics (Banin et al., 1998; Canman et al., 1998) . In order to determine whether ATR activation is involved in S407 phosphorylation, we introduced wild-type ATR (ATR (Figure 4a ). CPT treatment induces S407 phosphorylation by 6.6-fold in the absence of ATR, whereas the same treatment induces by 3.1-and 7.5-fold in the presence of ATR KI and ATR WT , respectively. Thus, introduction of ATR KI reduced CPT-dependent S407 phosphorylation by 2.1-fold, while introduction of ATR WT rather induced the phosphorylation. In contrast, phosphorylation of serine 166 was not significantly affected by introduction of either ATR WT or ATR KI into cells (Figure 4a ). These results indicate that ATR is specifically responsible for CPT-dependent S407 phosphorylation.
ATR specifically phosphorylates S407 in vitro
In order to determine if ATR directly phosphorylates S407, we performed in vitro phosphorylation assays. ATR KI and ATR WT were immunoprecipitated from transfected COS-1 cells (Figure 4b , upper panel), and were used to determine whether they can phosphorylate purified Mdm2. We did not observe any detectable phosphorylation of serine 166 in the presence of ATR KI or ATR WT . In contrast, S407 was significantly phosphorylated in the presence of ATR WT , while ATR KI had no effect on S407 phosphorylation (Figure 4b , lower panel). Taken together, these data strongly indicate that ATR is a major kinase that phosphorylates S407.
Substitution of S407 with aspartate but not with alanine attenuates Mdm2-dependent translocation of p53
Next, we attempted to determine the biological significance of S407 phosphorylation by ATR. It was previously demonstrated that ATR activates p53 after DNA damage or hypoxia Hammond et al., 2002) . Given Mdm2's role as a major inhibitor of p53, it is possible that phosphorylation of Mdm2 by ATR contributes to p53 activation after DNA Figure 3 S407 phosphorylation is associated with cell cycle arrest at S phase. (a) S407 phosphorylation is induced upon S phase cell cycle arrest after CPT treatment. CV-1 cells were grown in normal growth medium or incubated with medium containing 0.1% fetal calf serum for 48 h. Serum-starved cells were then incubated with normal growth medium for indicated times in the presence or the absence of 1 mM CPT. Subsequently, lysates were prepared from cells, and immunoprecipitations and Western blot analyses were performed as described in Figure 2c . Cell cycle progression into S phase was monitored by counting a number of cells that incorporate BrdU (see Materials and methods). (b) CPT-induced S407 phosphorylation was inhibited in the presence of caffeine or mimosine. CV-1 cells were treated with 1 mM CPT, 300 mM mimosine, and/or 10 mM caffeine for 24 h (CPT and mimosine) or 2 h (caffeine) before harvesting cells. Left panel: after drug treatment, cell cycle profiles were analysed by flow cytometry. Right panel: lysates prepared from drug-treated cells were used for immunoprecipitation of Mdm2 with IF-2. The Mdm2 immunoprecipitates were then used for Western blot analysis with IF-2 or with the anti-phospho-Mdm2 antibodies (the anti-phospho-S166 and -S407 antibodies). (c) S407 phosphorylation was induced after HU treatment. Left panel: CV-1 cells were incubated in the presence or the absence of 1 mM HU for 24 h, and cell cycle profiles were analysed by flow cytometry. Right panel: immunoprecipitation and Western blot analysis of Mdm2 derived from control and HU-treated cells were performed as described in Figure 3a Role of Mdm2 phosphorylation by ATR in p53 nuclear export T Shinozaki et al damage. In order to examine possible roles of phosphorylation of Mdm2 by ATR on p53 activity, we created Mdm2 mutants that harbor S407 or S395 substitution with aspartic acid and are presumed to mimic phosphorylated Mdm2 (S407D or S395D).
First, we examined Mdm2-dependent export of p53 from nuclei using Mdm2 mutants. Wild-type or mutant Mdm2 was transfected into U2OS cells together with p53, and the ability of Mdm2 to translocate p53 was evaluated by immunostaining of p53. In agreement with previous reports, the S395D mutant showed weaker activity than wild-type Mdm2 to translocate p53 from nuclei to cytoplasm (Maya et al., 2001) . Examination of the S407D mutant revealed that its ability for p53 translocation was also reduced in comparison to wildtype Mdm2 (Figure 5a) .
Next, we examined the activity of the Mdm2 mutant in which S407 was substituted with alanine (S407A). We observed the transfected S407A mutant was expressed at levels much lower than the other Mdm2 mutants or wild-type Mdm2, and a majority of cells that were transfected with S407A failed to express detectable Mdm2 (unpublished data). In order to precisely compare effects of the S407A mutant and wild-type Mdm2 on p53 localization, we performed a double immunostaining of both Mdm2 and p53, and examined localization of p53 in transfected cells that express detectable Mdm2. The RING finger mutant, C464A, which was defective in its ability to export p53 (Boyd et al., 2000; Geyer et al., 2000; Maya et al, 2001 ), showed significantly decreased activity to translocate p53 from nuclei to cytoplasm than wild-type Mdm2. Again, the S407D mutant was weaker than wild-type Mdm2 in its ability to export p53 from nuclei. In contrast, the activity of the S407A mutant to translocate p53 was comparable to that of wild-type Mdm2 (Figure 5b ). These data indicate that the integrity of S407 is important for Mdm2's function to translocate p53, and strongly suggest that phosphorylation of S407 attenuates Mdm2-dependent translocation of p53 from nuclei to cytoplasm.
Substitution of S407 with aspartate attenuates Mdm2-dependent downregulation of p53
The currently accepted view of the regulation of p53 level is that p53 is mainly degraded in cytoplasm where the main body of the proteosome machinery is located (Tao and Levine, 1999) , although there are several reports that p53 degradation can occur in nuclei as well as in cytoplasm (Xirodimas et al., 2001; Shirangi et al., 2002) .
Since S407D mutation attenuates Mdm2-dependent translocation of p53 from nuclei to cytoplasm, it is possible that total levels of p53 increase as a result of its nuclear retention after S407 phosphorylation by ATR. In order to determine if S407 phosphorylation affects p53 levels, we transfected p53 together with the S407D mutant and compared the effect of the mutant on p53 levels with that of wild-type Mdm2. As reported previously, the S395 mutant with aspartate substitution (S395D) is not capable of reducing p53 levels (Maya et al., 2001) . The S407D mutant showed weaker activity than wild-type p53 to reduce p53 levels, although the effect of the mutation on Mdm2's activity is modest compared to that of the S395D mutation (Figure 6a ). Taken together, the integrity of S407 as well as S395 is important for Mdm2's ability to export p53 from nuclei and to reduce p53 levels.
Discussion
Inactivation of Mdm2 plays a major role in activating p53 after cells are exposed to DNA damage or oncogenic activation. Considering that Mdm2 is a heavily phosphorylated protein and the complexed alteration of phosphorylation patterns of Mdm2 follows after DNA damage or induction of oncogenes (Henning et al., 1997; Hay and Meek, 2000; Blattner et al., 2002) , it is likely that phosphorylation of Mdm2 plays an important role in p53 activation. Although it was demonstrated that phosphorylation of Mdm2 by ATM or C-Abl kinase reduces Mdm2's ability to inactivate Role of Mdm2 phosphorylation by ATR in p53 nuclear export T Shinozaki et al p53 after DNA damage (Maya et al., 2001; Goldberg et al., 2002) , the significance of Mdm2 phosphorylation in regulation of p53 activity is largely unknown. In this paper, we presented data that indicate that ATR is responsible for phosphorylation of Mdm2 at serine 407 after DNA damage, and that Mdm2 phosphorylation by ATR leads to nuclear retention of p53 as a result of attenuated function of Mdm2. It was previously reported that ATR is responsible for activation of p53 via direct phosphorylation at serine 15. Therefore, we propose that ATR can induce nuclear accumulation of p53 through phosphorylation of two different substrates, namely p53 itself and its major inhibitor, Mdm2. Thus, our data strengthen the link between ATR and the Mdm2-p53 pathway.
ATR plays an important role in DNA damage checkpoint and functions as a safeguard for DNA replication (Abraham, 2001) , and its activation is associated with inhibition of DNA replication after DNA damage (Brown and Baltimore, 2000; Lupardus et al., 2002) . The data presented in Figures 2 and 3 , namely induction of S407 phosphorylation by HU and CPT and the phosphorylation upon entry into S phase, are in good agreement with documented profiles of phosphorylation by ATR in response to damaged DNA replication.
While ATR is necessary for early embryonic development (Brown and Baltimore, 2000; Lupardus et al., 2002) , disruption of ATR function leads to perturbation of DNA repair function and loss of cell cycle arrest in S and G2 phases after DNA damage (Cliby et al., 1998; Nghiem et al., 2002) . Known substrates for ATR include BRCA1, Chk2, and Rad17, and these targets are likely to be pivotal transducers for the DNA damage checkpoint pathway (Cortez et al., 1999 ; Tibbetts et al., Figure 6 (a) S407 mutation affects Mdm2-dependent downregulation of p53. Upper panel: a substitution of S407 or S395 with aspartate compromises Mdm2-dependent downregulation of p53. HA-tagged p53 (15 ng) and GFP (20 ng) were cotransfected into H1299 cells together with 100, 300, 600, or 900 ng of wild-type or mutant Flag-tagged Mdm2. At 24 h after transfection, lysates were prepared from the transfected cells, and used for Western blot analysis to determine levels of transfected p53 with the anti-p53 monoclonal antibodies (DO-1 plus 1801). Western blot analyses of transfected Mdm2 and GFP were performed with the anti-Flag antibody (M2) and anti-GFP monoclonal antibody (Clonetech), respectively. Lower panel: the results shown in the upper panel are quantified by densitometry, and normalized by calculating p53/ GFP ratio. (b) S407 mutations do not significantly affect Mdm2-dependent inhibition of trans-activation by p53. In total, 100 ng of the bax promoter-driven luciferase plasmid (Gaiddon et al., 2001) was transfected into CV-1 cells together with the control vector (lane 1), 50 ng of p53 alone (lane 2), or 50 ng of p53 and 1 mg of indicated Mdm2. Lucifease activities were measured 24 h after transfection. Diagrams represent means from two independent experiments, and are shown as fold induction in comparison with the luciferase activity from cells transfected with the control vector. (c) S407 mutations do not significantly affect Mdm2-dependent multiubiquitination of p53. A total of 2 mg of the control vector (lane 1) or HA-tagged p53 (lanes 2-5) was transfected into H1299 cells together with 4 mg of His-tagged ubiquitin and 12 mg of indicated Mdm2. At 46 h after transfection, cells were incubated with 50 mM MG132 for 2 h, and lysates prepared from transfected cells were used for immunoprecipitaion with the anti-HA antibody (Covance). Western blot analyses of the immunoprecipitates were performed with the anti-His antibody (Santa-cruz) to detect ubiquitinated p53 (the upper lane), or with DO-1 to detect nonubiquitinated p53 (the lower lane). Asterisks indicate nonspecific bands Role of Mdm2 phosphorylation by ATR in p53 nuclear export T Shinozaki et al 1999; Liu et al., 2000; Bao et al., 2001) . Our data indicate that Mdm2 may also contribute to the ATRdependent pathway. Phosphorylation of Mdm2 on S407 and subsequent activation of p53 may contribute to modulate DNA repair or to trigger cell cycle arrest.
It was reported that Mdm2's RING finger domain, the catalytic domain responsible for the E3 ubiquitin ligase activity for p53, is required for nuclear export of p53 (Boyd et al., 2000; Geyer et al., 2000) . In fact, Mdm2-dependent multiple monoubiquitination of p53 is responsible for its nuclear export (Gu et al., 2001; Lohrum et al., 2001) . Given the proximity of S395 and S407 to the RING finger domain, it is possible that S395 or S407 phosphorylation compromises Mdm2-dependent export of p53 by inhibiting the ubiquitin ligase activity of Mdm2. However, when p53 was introduced into CV-1 cells together with either wild-type or the S407 mutant of Mdm2 to compare their effects on p53 ubiquitination, we did not find any observable differences of laddering pattern of p53 generated by Mdm2-dependent multiubiquitination of p53 (Figure 6c ). Therefore, it is not likely that decreased nuclear export of p53 by S407 phosphorylation is caused by decreased polyubiquitination of p53. It is still possible, however, that there exists a specific p53 ubiquitination site that is responsible for nuclear export, and phosphorylation of S407 inhibits ubiquitination of specific lysine residues of p53. In this context, it will be interesting to examine the extent of ubiquitination in each ubiquitinated site in the presence of wild-type or mutant Mdm2 in order to determine the specificity of individual ubiquitination.
Since analyses of S407 mutants in Figures 5 indicate that phosphorylation of S407 promotes nuclear retention of p53, we examined if S407 mutation affects Mdm2-dependent inhibition of the trans-activating function of p53. The results obtained from luciferase assays indicate that activity of Mdm2 to inhibit the trans-activating function of p53 is not significantly affected by S407D mutation (Figure 6b ). These data imply that p53 which accumulates in nuclei after Mdm2 phosphorylation by ATR is transcriptionally inactive. Indeed, it was previously reported that p53 induced after replication arrest is functionally impaired (Gottifredi et al., 2001; Takimoto and El-Deiry, 2001 ). Presumably p53 that is activated after replication block has transcription-independent roles in the ATR-driven DNA damage checkpoint.
Materials and methods
Plasmids
The construction of expression vectors encoding HA-tagged human p53 (pCMV-HA p53) and Flag-tagged human wildtype mdm2 (pSG-F-hdm2) was previously described (Pochampally et al., 1999; Gaiddon et al., 2001) . The Mdm2 mutants with alanine or aspartate substitution (S407A, S407D, S395A, S395D, or C464A) were created using the quikchange sitedirected mutagenesis kit (Stratagene) according to the manufacturer's instructions. The construction of the ATR expression vectors was previously described (Tibbetts et al., 2000) . To create pGST-hdm2, cDNA that corresponds to the open reading frame of human Mdm2 was amplified by polymerase chain reaction, and inserted in frame into the EcoRI-XhoI sites of pGEX-KG (Guan and Dixon, 1991).
Antibodies
The anti-Mdm2 monoclonal antibody, IF2, was purchased from Oncogene Science. The anti-HA antibody was purchased from Babco. The anti-Flag antibody (M2) conjugated with Sepharose was purchased from Sigma, and purified anti-Flag antibody from Santa Cruz. The anti-phospho-S407 was raised against a phosphopeptide corresponding to the sequences that span serine 407 (SIIYSSQEDVKC). The antibody was affinity-purified on the identical peptide, followed by immunodepletion of nonspecific antibody with the nonphosphorylated peptide that corresponds to the identical peptide sequence (Taya et al., in press ). The anti-phospho-166 antibody was previously described (Okamoto et al., 2002) .
Cells and transfection
CV-1, H1299, and U2OS cells were maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal calf serum (GIBCO BRL). In DNA transfection experiments using H1299 cells, 1 mg of DNA and 3 ml of fugene6 reagent (Roche) were introduced per 1.0 Â 10 5 cells. Cells were then incubated for 24 h after transfection. In DNA transfection experiments using U2OS cells for immunostaining, 0.5 mg of DNA were introduced into 1.0 Â 10 5 cells using lipofectamine plus (Invitrogen) according to the manufacturer's instructions. In DNA transfection experiments using CV-1 cells for immunostaining, 2 mg of DNA and 6 ml of fugene6 (Roche) were introduced into 1.0 Â 10 5 cells according to the manufacturer's instructions.
Immunoprecipitation and Western analysis
For immunoprecipitation of cell lysates, cells were washed in PBS and lysed in NETN buffer (50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 0.1% Nonidet P-40, 1 mM EDTA, 1 mM DTT) supplemented with 1 mg/ml N-methylmaleimide (Sigma), PI cocktail (10 mg/ml antipain, 10 mg/ml leupeptin, 10 mg/ml pepstatin, 10 mg/ml chymostatin, 10 mg/ml E64, 10 mg/ml APMSF), and Phl cocktail (0.1 mM Na 3 VO 4 , 10 mM NaF). Lysates were then centrifuged at 20 000 g for 10 min, and supernatants were incubated with appropriate antibodies in the presence of Protein G-Sepharose (Pharmacia) for 2 h. Immunoprecipitates were then washed four times with NETN buffer. For Western blotting analysis, immunoprecipitates were boiled in Laemmli sample buffer, separated by SDS-PAGE, and transferred to PVDF membrane (Millipore). Membranes were blocked with 10% nonfat dried milk in TBST Buffer (20 mM Tris-HCl (7.5), 140 mM NaCl, 0.1% Tween-20) and probed with appropriate antibodies.
In vitro kinase assays
To purify the GST-Mdm2 fusion protein, E. Coli strain BL21(DE3) was transformed with the bacterial expression plasmid that expresses the GST-Mdm2 fusion protein. The transformed bacteria were grown at 301C in 2 l of LB medium until cell density reached B1.0 at O.D. 600. The fusion protein was then expressed by adding 0.1 mM IPTG to the medium for 3 h. Subsequently, cells were harvested, lysed in GST column buffer (50 mM Tris-HCl (7.5), 100 mM NaCl, 1 mM EDTA, 1% NP-40, 5 mM DTT), and purified on glutathione sepharose resin (Pharmacia). The fusion protein was eluted with GST column buffer supplemented with 20 mM glutathione, and dialysed against GST dialysis buffer (50 mM Tris-HCl (7.5), 100 mM NaCl, 20% glycerol, 0.1 mM EDTA, 0.05% NP-40, 5 mM DTT) supplemented with PI cocktail. For kinase assays, the plasmid that expresses wild-type or a dominant-negative form of ATR was transfected into COS-1 cells, and lysates prepared from transfected cells were used to immunoprecipitate ATR on agarose resin conjugated with anti-Flag M2 antibody (Sigma). Immunoprecipitated ATR or the control immunoprecipitate from mock-transfected cells was then incubated with GST-Mdm2 in in vitro kinase buffer (10 mM Tris-HCl (7.5), 50 mM NaCl, 10 mM MgCl 2 , 1mM DTT) supplemented with PI cocktail, Phl cocktail, and 1 mM ATP. The kinase reactions were performed at 301C for 15 or 30 min, and stopped by adding 2 Â Laemmli loading buffer. The samples were then boiled, and separated by SDS-PAGE gel to analyse phosphorylation of Mdm2 by Western blot analysis.
Immunostaining
After DNA transfection, CV-1 or U2OS cells were fixed in 4% paraformaldehyde/PBS for 10 min, washed with 1 Â PBS, and permealized in 100% methanol for 30 min at À201C. Cells were then rehydrated in 1 Â PBS, incubated with blocking buffer (20% goat serum (Sigma, 3% bovine serum albumin (BSA)/10 mM glycine/1 Â PBS) for 1 h, and used for immunostaining with appropriate primary antibodies for 1 h. Cells were washed in the wash buffer (1% BSA/10 mM glycine/ 1 Â PBS) and incubated with the appropriate secondary antibody conjugated with Alexa Fluor 488 or Alexa Fluor 594 (Molecular Probe). For BrdU immunostaining described in Figure 3a , cells were incubated with 10 mM BrdU for 1 h at the indicated times. Cells were then fixed in 4% paraformaldehyde/PBS for 10 min and washed with 1XPBS. After permealization in 0.2% Nonidet P-40/PBS for 5 min, cells were treated with 4 N HCl for 10 min, and used for immunostaining with the anti-BrdU antibody conjugated with FITC (Roche). Subsequently, 200 cells from each sample were counted for BrdU incorporation.
